Dr. Roderick McInnes, Director of the Lady Davis Institute at the JGH, is being honoured with the 2017 Distinguished Scientist Award by the Canadian Society for Clinical Investigation.
In the ongoing fight against dementia, a research team in the Lady Davis Institute, is looking at electro-magnetic stimulation as a method of targeting the illness through the brain’s electrical impulses.
Research by Dr. Jonathan Afilalo has revealed that frailty is a major risk factor for death and disability after two types of cardiac surgical procedures.
The Canadian Task Force on Preventive Health Care has recommended against screening for chronic hepatitis C virus (HCV) in adults who are at low risk.
Although there is little scientific evidence that behaviour can be changed with the help of neurofeedback, some benefits may still result from the technique’s placebo effects.
A unique phase 2 clinical trial, led by researchers in the Segal Cancer Centre at the JGH, has resulted in a remission of diffuse large B-cell lymphoma for patients who have relapsed and have a particularly dire prognosis.
Potential exists for mobile apps to play a greater role in mental health care, such as the app that helps to assess the causes of stress in a patient’s day-to-day activities.
A renewed five-year mandate has been granted to a national consortium on prescription drug safety that is headquartered in the Lady Davis Institute at the JGH.